GT200600197A - Compuestos y composiciones como inhibidores de proteina quinasa - Google Patents
Compuestos y composiciones como inhibidores de proteina quinasaInfo
- Publication number
- GT200600197A GT200600197A GT200600197A GT200600197A GT200600197A GT 200600197 A GT200600197 A GT 200600197A GT 200600197 A GT200600197 A GT 200600197A GT 200600197 A GT200600197 A GT 200600197A GT 200600197 A GT200600197 A GT 200600197A
- Authority
- GT
- Guatemala
- Prior art keywords
- compounds
- compositions
- protein
- inhibitors
- quinasa inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE LA FÓRMULA GENERAL I EN LA QUE R1,R2,R3,R4,R7,Y1,Y2,M,N, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON DE UTILIDAD CON EL FIN DE TRATAR O PREVENIR ENFERMEDADES O TRASTORNOS ASOCIADOS CON UNA ACTIVIDAD DE QUINASA ANORMAL O MAL REGULADA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68068405P | 2005-05-13 | 2005-05-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200600197A true GT200600197A (es) | 2007-03-28 |
Family
ID=37074687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200600197A GT200600197A (es) | 2005-05-13 | 2006-05-10 | Compuestos y composiciones como inhibidores de proteina quinasa |
Country Status (19)
Country | Link |
---|---|
US (1) | US8183248B2 (es) |
EP (1) | EP1891066B1 (es) |
JP (1) | JP5016593B2 (es) |
KR (1) | KR20080025039A (es) |
CN (1) | CN101175753B (es) |
AR (1) | AR056346A1 (es) |
AT (1) | ATE492545T1 (es) |
AU (1) | AU2006247757B2 (es) |
BR (1) | BRPI0610278A2 (es) |
CA (1) | CA2607299C (es) |
DE (1) | DE602006019088D1 (es) |
ES (1) | ES2358344T3 (es) |
GT (1) | GT200600197A (es) |
MX (1) | MX2007014066A (es) |
PE (1) | PE20061366A1 (es) |
PL (1) | PL1891066T3 (es) |
RU (1) | RU2411242C2 (es) |
TW (1) | TW200726766A (es) |
WO (1) | WO2006124462A2 (es) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101296928B (zh) * | 2005-10-28 | 2011-01-19 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
US8809273B2 (en) | 2007-03-28 | 2014-08-19 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
CN101674834B (zh) * | 2007-03-28 | 2013-06-12 | 环状药物公司 | 布鲁顿氏酪氨酸激酶(Bruton's tyrosine kinase)抑制剂 |
EP2070929A1 (en) | 2007-12-11 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
AR070535A1 (es) * | 2008-02-29 | 2010-04-14 | Array Biopharma Inc | Compuestos inhibidores de raf y metodos para usarlos |
PE20091623A1 (es) * | 2008-02-29 | 2009-11-19 | Array Biopharma Inc | DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA |
WO2009111280A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
CA2716947A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imidazo [4,5-b] pyridine derivatives used as raf inhibitors |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
EP3210609A1 (en) | 2008-05-21 | 2017-08-30 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
EP2307456B1 (en) | 2008-06-27 | 2014-10-15 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
US20110224235A1 (en) | 2008-07-16 | 2011-09-15 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
US20120329826A1 (en) * | 2010-03-03 | 2012-12-27 | OSI Pharmaceuticals,. LLC | Substituted-5-aminopyrrolo/pyrazolopyridines |
NZ772688A (en) | 2010-06-03 | 2022-09-30 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
BR112013027734A2 (pt) | 2011-05-04 | 2017-08-08 | Ariad Pharma Inc | compostos para a inibição de proliferação celular em cânceres impulsionados pelo egfr, método e composição farmacêutica |
ES2548414T3 (es) | 2011-07-08 | 2015-10-16 | Novartis Ag | Novedosos derivados de pirrolo pirimidina |
AU2012283775A1 (en) | 2011-07-13 | 2014-01-23 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
CN103073508B (zh) * | 2011-10-25 | 2016-06-01 | 北京大学深圳研究生院 | 激酶抑制剂及治疗相关疾病的方法 |
US9782406B2 (en) | 2011-10-25 | 2017-10-10 | Peking University Shenzhen Graduate School | Kinase inhibitor and method for treatment of related diseases |
JP2015504876A (ja) * | 2011-12-22 | 2015-02-16 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | セリン/トレオニンキナーゼ阻害剤としての2,4−ジアミン−ピリミジン誘導体 |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Egfr発動性がんの細胞増殖阻害用化合物 |
NZ702548A (en) | 2012-06-04 | 2015-11-27 | Pharmacyclics Llc | Crystalline forms of a bruton’s tyrosine kinase inhibitor |
IL289834B1 (en) | 2012-06-13 | 2024-03-01 | Incyte Holdings Corp | Conversion of tricyclic compounds as FGFR inhibitors |
KR20180088926A (ko) | 2012-07-24 | 2018-08-07 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이 |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
JP2015537033A (ja) | 2012-11-15 | 2015-12-24 | ファーマサイクリックス,インク. | キナーゼ阻害剤としてのピロロピリミジン化合物 |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
WO2014145576A2 (en) | 2013-03-15 | 2014-09-18 | Northwestern University | Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
SG10201708520YA (en) | 2013-04-19 | 2017-12-28 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
TWI649081B (zh) | 2013-08-02 | 2019-02-01 | 製藥公司 | 治療固態腫瘤之方法 |
CA2920534A1 (en) | 2013-08-12 | 2015-02-19 | Pharmacyclics Llc | Methods for the treatment of her2 amplified cancer |
AU2014324532A1 (en) | 2013-09-30 | 2016-04-21 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
CA2942528A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics Inc. | Phospholipase c gamma 2 and resistance associated mutations |
AU2015296215A1 (en) | 2014-08-01 | 2017-03-23 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
BR112017002231A2 (pt) | 2014-08-07 | 2018-07-17 | Pharmacyclics Llc | novas formulações de um inibidor de tirosina cinase de bruton |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MX2017010673A (es) | 2015-02-20 | 2018-03-21 | Incyte Corp | Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr). |
SG10202102078VA (en) | 2015-03-03 | 2021-04-29 | Pharmacyclics Llc | Pharmaceutical formulations of a bruton’s tyrosine kinase inhibitor |
CN105801584B (zh) * | 2016-03-16 | 2019-03-05 | 中国药科大学 | 新型芳酰胺类Raf激酶抑制剂及其制备方法和用途 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
CR20200590A (es) | 2018-05-04 | 2021-04-26 | Incyte Corp | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas |
CN109374896A (zh) * | 2018-11-22 | 2019-02-22 | 中山大学孙逸仙纪念医院 | Plk3***癌预后诊断检测试剂及其试剂盒 |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
JP2022552324A (ja) | 2019-10-14 | 2022-12-15 | インサイト・コーポレイション | Fgfr阻害剤としての二環式複素環 |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
US11897891B2 (en) | 2019-12-04 | 2024-02-13 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ID26698A (id) | 1998-06-19 | 2001-02-01 | Pfizer Prod Inc | SENYAWA-SENYAWA PIROLO [2,3-d] PIRIMIDINA |
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
EP1382339B1 (en) | 1999-12-10 | 2007-12-05 | Pfizer Products Inc. | Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives |
NZ522364A (en) | 2000-06-26 | 2004-09-24 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents |
EP1656378A4 (en) | 2003-08-15 | 2011-05-11 | Irm Llc | COMPOUNDS AND COMPOSITIONS INHIBITING TYROSINE KINASE RECEPTOR ACTIVITY |
US7338957B2 (en) | 2003-08-28 | 2008-03-04 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
-
2006
- 2006-05-10 KR KR1020077026230A patent/KR20080025039A/ko not_active Application Discontinuation
- 2006-05-10 MX MX2007014066A patent/MX2007014066A/es active IP Right Grant
- 2006-05-10 WO PCT/US2006/018096 patent/WO2006124462A2/en active Application Filing
- 2006-05-10 PL PL06752481T patent/PL1891066T3/pl unknown
- 2006-05-10 JP JP2008511323A patent/JP5016593B2/ja not_active Expired - Fee Related
- 2006-05-10 EP EP06752481A patent/EP1891066B1/en not_active Not-in-force
- 2006-05-10 AU AU2006247757A patent/AU2006247757B2/en not_active Ceased
- 2006-05-10 CN CN2006800161327A patent/CN101175753B/zh not_active Expired - Fee Related
- 2006-05-10 GT GT200600197A patent/GT200600197A/es unknown
- 2006-05-10 AT AT06752481T patent/ATE492545T1/de active
- 2006-05-10 US US11/914,308 patent/US8183248B2/en not_active Expired - Fee Related
- 2006-05-10 BR BRPI0610278-6A patent/BRPI0610278A2/pt not_active IP Right Cessation
- 2006-05-10 ES ES06752481T patent/ES2358344T3/es active Active
- 2006-05-10 CA CA2607299A patent/CA2607299C/en not_active Expired - Fee Related
- 2006-05-10 DE DE602006019088T patent/DE602006019088D1/de active Active
- 2006-05-10 RU RU2007145935/04A patent/RU2411242C2/ru not_active IP Right Cessation
- 2006-05-11 AR ARP060101900A patent/AR056346A1/es unknown
- 2006-05-11 PE PE2006000501A patent/PE20061366A1/es not_active Application Discontinuation
- 2006-05-12 TW TW095116981A patent/TW200726766A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0610278A2 (pt) | 2010-06-08 |
JP2008540556A (ja) | 2008-11-20 |
DE602006019088D1 (de) | 2011-02-03 |
TW200726766A (en) | 2007-07-16 |
JP5016593B2 (ja) | 2012-09-05 |
CA2607299A1 (en) | 2006-11-23 |
CN101175753A (zh) | 2008-05-07 |
PE20061366A1 (es) | 2007-01-05 |
AR056346A1 (es) | 2007-10-03 |
AU2006247757A1 (en) | 2006-11-23 |
AU2006247757B2 (en) | 2009-08-27 |
KR20080025039A (ko) | 2008-03-19 |
MX2007014066A (es) | 2008-02-11 |
WO2006124462A3 (en) | 2007-01-04 |
CN101175753B (zh) | 2011-03-23 |
EP1891066A2 (en) | 2008-02-27 |
WO2006124462A2 (en) | 2006-11-23 |
RU2007145935A (ru) | 2009-06-20 |
ES2358344T3 (es) | 2011-05-09 |
RU2411242C2 (ru) | 2011-02-10 |
ATE492545T1 (de) | 2011-01-15 |
EP1891066B1 (en) | 2010-12-22 |
US20090118273A1 (en) | 2009-05-07 |
PL1891066T3 (pl) | 2011-05-31 |
US8183248B2 (en) | 2012-05-22 |
CA2607299C (en) | 2013-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200600197A (es) | Compuestos y composiciones como inhibidores de proteina quinasa | |
GT200600174A (es) | Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion | |
GT200800258A (es) | Compuestos de pirrolo-pirimidina y sus usos | |
CU20120071A7 (es) | DERIVADOS DE N1-PIRAZOLOESPIROCETONA ÚTILES COMO INHIBIDORES DE ACETIL-CoA CARBOXILASA | |
GT200500242A (es) | Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas | |
GT200600167A (es) | Derivados de dihidrobenzofurano y usos de los mismos | |
GT200500103A (es) | 4-fenilamino-quinazolin-6-il-amidas | |
GT200700039A (es) | Derivados de triazolopirazina | |
GT200500292A (es) | Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica | |
GT200500218A (es) | Derivados de triazolopiridinilsulfanilo como inhibidores de quinasa map p38 | |
ECSP088210A (es) | Bencimidazoles sustituidos y métodos de preparación | |
GT200600030A (es) | 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2 | |
ATE548374T1 (de) | 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren | |
PA8667201A1 (es) | Nuevos compuestos farmaceuticos | |
PA8842101A1 (es) | Heteroarilos sustituidos | |
UY31984A (es) | DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas. | |
CR11264A (es) | Compuestos de 5-(4-halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa | |
GT200600024A (es) | Derivados de triazol sustituidos como antagonistas de oxitocina | |
ECSP088676A (es) | Pirazolquinolonas como potentes inhibidores de parp | |
GT200500215A (es) | Amidas sustituidas de àcido tienopirrolcarboxìlico, amidas del àcido pirrolotiazolcarboxìlico y anàlogos relacionados como inhibidores de la epsilon caseìna quinasa i | |
UY30052A1 (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
GT200500051A (es) | Nuevos derivados de bencil (ideno)-lactamas | |
GT200300033A (es) | Derivados de nicotinamida utiles como inhibidores de pde4 | |
CR20110381A (es) | Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2 | |
PA8855001A1 (es) | Monocarbamas |